Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corautus gets US fast track status angina gene therapy :

This article was originally published in Clinica

Executive Summary

The US FDA has designated Corautus Genetics' gene therapy treatment for severe angina fast track status, a classification designed to help companies accelerate a product's development to commercialisation. The vascular endothelial growth factor 2 (VEGF-2) treatment, which is being developed in collaboration with Boston Scientific, is intended to promote therapeutic angiogenesis in ischaemic muscle; trials are underway to assess VEGF-2 delivered percutaneously via Boston's Stiletto endocardial direct injection catheter system. Fast track-designated products are eligible for priority review - six months versus the average 12 months - and/or the review of portions of the marketing application prior to the completion of the final registration package.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel